Evidence map›Paper›PMID 38530585›Full record

ArticleInternational urology and nephrology2024

Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.

Mariana Silva Medeiros, Luís André Botelho de Carvalho, Marta Alves, Ana Papoila, Hugo Miguel Baptista Carreira Dos Santos, José-Luis Capelo-Martínez, Luís Manuel Viegas de Campos Pinheiro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Mariana Silva MedeirosDepartment of Urology, Central Lisbon University Hospital Centre, Lisbon, Portugal. mmariana.medeiros92@gmail.com.ORCID http://orcid.org/0009-0006-6152-4555
Luís André Botelho de CarvalhoDepartment of Chemistry, Faculty of Science and Technology, Caparica, Portugal.
Marta AlvesEpidemiology and Statistics Unit, Research Centre, Central Lisbon University Hospital Centre, Lisbon, Portugal.
Ana PapoilaEpidemiology and Statistics Unit, Research Centre, Central Lisbon University Hospital Centre, Lisbon, Portugal.
Hugo Miguel Baptista Carreira Dos SantosDepartment of Chemistry, Faculty of Science and Technology, Caparica, Portugal.
José-Luis Capelo-MartínezDepartment of Chemistry, Faculty of Science and Technology, Caparica, Portugal.
Luís Manuel Viegas de Campos PinheiroDepartment of Urology, Central Lisbon University Hospital Centre, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeT1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin/myeloperoxidase (CUBN/MPO) ratio as a high-grade T1 bladder cancer biomarker.

methodsUrine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5 months after resection). Univariate Cox regression and Kaplan-Meier curves were used for data analysis.

resultsPatients with a low CUBN/MPO ratio exhibited upregulated MPO and/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts.

conclusionThis study highlights the potential of the CUBN/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer.

Indexed as

Biomarkers, TumorNeoplasm GradingNeoplasm StagingPeroxidaseUrinary Bladder NeoplasmsAgedFemaleHumansMaleMiddle AgedPrognosisReceptors, Cell SurfaceBiomarkers, Tumorintrinsic factor-cobalamin receptorPeroxidaseReceptors, Cell SurfaceCUBN/MPONon-muscle-invasive bladder cancerRecurrenceUrinary proteome

Identifiers

PMID38530585
PMCPMC11266244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.